EUROAPI Announces €50 Million Investment in Budapest Site to Meet Increasing Prostaglandin Demand
Introduction:
EUROAPI, a pharmaceutical company has revealed its plans to invest €50 million in constructing a state-of-the-art production plant at its Budapest site. This significant investment is aimed at expanding.
Features:
EUROAPI's manufacturing capabilities and satisfying the increasing demand for its pharmaceutical products.
The purpose of the investment is to meet the increasing demand for prostaglandins.
The project involves two phases: debottlenecking the current capacity and constructing new multi-purpose manufacturing equipment.
By 2027, the prostaglandin capacity at the Budapest site is expected to more than double.
Prostaglandins have an annual sales market worth approximately €5 billion.
The prostaglandin market is projected to grow at a compound annual growth rate (CAGR) of 5-7% between 2022 and 2027.
EUROAPI is the sole Western supplier with a complete portfolio of prostaglandins and an integrated production site in Europe.
This investment demonstrates EUROAPI's commitment to serving clients in distinct health product segments.
The new facility will prioritize environmental sustainability through a modern air handling system, energy-efficient design, and closed waste handling.
The facility will also have the capability for highly potent-API (HP-API) development.
The investment in the EUROAPI Budapest facility will be carried out in two distinct phases: the first phase from 2023 to 2025, and the second phase from 2026 to 2027.
Specifications:
Name: EUROAPI
Type: Expansion
Year: 2026-2027
